Can a Clot-Boosting drug beat adrenaline for airway bleeding?
NCT ID NCT07759089
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This trial tests whether tranexamic acid, a medicine that helps blood clot, stops airway bleeding after a biopsy better than adrenaline, the current standard. Adults who develop moderate bleeding during a bronchoscopy biopsy will receive one of the two medicines directly on the bleeding spot. The study aims to see which drug stops bleeding faster and prevents it from restarting within 30 minutes.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Tranexamic acid and adrenaline, both given directly onto the bleeding site through a bronchoscope
- What this could lead to
- If tranexamic acid works better, it could become the preferred treatment for stopping airway bleeding during bronchoscopy, reducing complications and repeat procedures.
- What could go wrong
- This is a small, early-stage trial, and results may not apply to all patients. Both drugs have risks, and tranexamic acid might not prove superior to the current standard.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
76 people
The number who actually took part.
- Started
-
Jan 2022
- Finished
-
Jan 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult patients of any age and gender undergoing diagnostic flexible bronchoscopy for suspected benign or malignant airway disease * Required endobronchial forceps biopsy during the procedure * Developed moderate endobronchial bleeding following biopsy (defined as bleeding that obscured the bronchoscopic view, required repeated suctioning to clear the airway, and required endoscopic intervention for hemostasis, but remained hemodynamically stable) Exclusion Criteria: * Severe bleeding (requiring instillation of ice-cold saline, bronchoscopic tamponade, electrocautery, or argon plasma coagulation) * Life-threatening bleeding (requiring endotracheal intubation, or spontaneous hemoptysis of more than 100-150 mL per hour) * Contraindications to bronchoscopy, including: 1. Cardiac arrhythmias 2. Oxygen saturation below 90% on supplemental oxygen 3. Acute respiratory failure with hypercapnia 4. Tracheal obstruction * Bleeding diathesis with raised INR or platelet count less than 50,000/mm³ * Unstable coronary artery disease * Hypersensitivity to tranexamic acid or adrenaline
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Endobronchial bleeding are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sheikh Zayed Hospital
Lahore, Punjab Province, 54470, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.